保护医疗保健和患者通道免受感染和抗微生物药物耐药性的影响。
Protecting healthcare and patient pathways from infection and antimicrobial resistance.
机构信息
David Price Evans Global Health and Infectious Diseases Research Group, University of Liverpool, Liverpool, UK
NIHR Royal Liverpool and Broadgreen Clinical Research Facility, Liverpool, UK.
出版信息
BMJ. 2024 Oct 7;387:e077927. doi: 10.1136/bmj-2023-077927.
Abstract
Innovative whole system approaches to integrate research and novel technologies within patient pathways are needed to target antibiotic use, minimise healthcare associated infections, and adapt to novel pathogens, write
摘要
需要创新的整体系统方法，将研究和新技术整合到患者路径中，以针对抗生素使用、最大限度地减少医疗保健相关感染，并适应新出现的病原体，
相似文献
1
Protecting healthcare and patient pathways from infection and antimicrobial resistance.保护医疗保健和患者通道免受感染和抗微生物药物耐药性的影响。
BMJ. 2024 Oct 7;387:e077927. doi: 10.1136/bmj-2023-077927.
2
Antimicrobial resistance stewardship: it's up to us all.抗菌药物耐药性管理：这取决于我们所有人。
Int J Orthop Trauma Nurs. 2018 Feb;28:1-3. doi: 10.1016/j.ijotn.2017.11.004. Epub 2017 Dec 2.
3
Antimicrobial Resistance: An Antimicrobial/Diagnostic Stewardship and Infection Prevention Approach.抗微生物药物耐药性：抗微生物药物/诊断管理与感染预防方法。
Med Clin North Am. 2018 Sep;102(5):819-829. doi: 10.1016/j.mcna.2018.04.005. Epub 2018 Jun 27.
4
Nationwide multicenter questionnaire surveys on countermeasures against antimicrobial resistance and infections in hospitals.全国多中心医院抗菌药物耐药与感染防控措施问卷调查
BMC Infect Dis. 2021 Feb 27;21(1):234. doi: 10.1186/s12879-021-05921-2.
5
Antimicrobial Stewardship and the Infection Control Practitioner: A Natural Alliance.抗菌药物管理与感染控制从业者：天然的联盟。
Infect Dis Clin North Am. 2021 Sep;35(3):771-787. doi: 10.1016/j.idc.2021.04.011.
6
Workshop on antimicrobial resistance in hospitals. Society for Healthcare Epidemiology of America.医院抗微生物药物耐药性研讨会。美国医疗保健流行病学学会。
Infect Control Hosp Epidemiol. 1995 Feb;16(2):120.
7
Addressing the Problem of Multidrug-Resistant Organisms in Dialysis.解决透析中多重耐药菌的问题。
Clin J Am Soc Nephrol. 2018 Apr 6;13(4):666-668. doi: 10.2215/CJN.13781217. Epub 2018 Mar 22.
8
Implementation research for the prevention of antimicrobial resistance and healthcare-associated infections; 2017 Geneva infection prevention and control (IPC)-think tank (part 1).预防抗菌药物耐药和医源性感染的实施研究；2017 年日内瓦感染预防和控制（IPC）-智库（第 1 部分）。
Antimicrob Resist Infect Control. 2019 May 28;8:87. doi: 10.1186/s13756-019-0527-1. eCollection 2019.
9
Antimicrobial Stewardship and Infection Prevention-Leveraging the Synergy: A Position Paper Update.抗菌药物管理与感染预防——发挥协同作用：立场文件更新
Infect Control Hosp Epidemiol. 2018 Apr;39(4):467-472. doi: 10.1017/ice.2018.33.
10
Principles and Practice of Antibiotic Stewardship in the ICU.《重症加强治疗病房抗生素管理实践原则》。
Chest. 2019 Jul;156(1):163-171. doi: 10.1016/j.chest.2019.01.013. Epub 2019 Jan 25.
引用本文的文献
1
Compliance with transmission-based precautions, and associated factors among healthcare providers in Cameroon: a cross-sectional study.喀麦隆医疗服务提供者对基于传播的预防措施的依从性及其相关因素：一项横断面研究。
Antimicrob Resist Infect Control. 2025 Mar 11;14(1):21. doi: 10.1186/s13756-025-01523-8.
2
World Health Organization priority antimicrobial resistance in and healthcare-associated bloodstream infections in Brazil (ASCENSION): a prospective, multicentre, observational study.世界卫生组织确定的巴西医院获得性血流感染的重点抗菌药物耐药性（ASCENSION）：一项前瞻性、多中心观察性研究。
Lancet Reg Health Am. 2025 Jan 30;43:101004. doi: 10.1016/j.lana.2025.101004. eCollection 2025 Mar.
本文引用的文献
1
Costs-effectiveness and cost components of pharmaceutical and non-pharmaceutical interventions affecting antibiotic resistance outcomes in hospital patients: a systematic literature review.影响医院患者抗生素耐药性结果的药物和非药物干预措施的成本效益和成本构成：系统文献回顾。
BMJ Glob Health. 2024 Feb 29;9(2):e013205. doi: 10.1136/bmjgh-2023-013205.
2
Genomics for antimicrobial resistance surveillance to support infection prevention and control in health-care facilities.用于抗菌药物耐药性监测的基因组学，以支持医疗机构中的感染预防与控制。
Lancet Microbe. 2023 Dec;4(12):e1040-e1046. doi: 10.1016/S2666-5247(23)00282-3. Epub 2023 Nov 14.
3
The burden and dynamics of hospital-acquired SARS-CoV-2 in England.英格兰医院获得性 SARS-CoV-2 的负担和动态。
Nature. 2023 Nov;623(7985):132-138. doi: 10.1038/s41586-023-06634-z. Epub 2023 Oct 18.
4
Implications of reducing antibiotic treatment duration for antimicrobial resistance in hospital settings: A modelling study and meta-analysis.减少医院环境中抗生素治疗时间对抗菌药物耐药性的影响：建模研究和荟萃分析。
PLoS Med. 2023 Jun 15;20(6):e1004013. doi: 10.1371/journal.pmed.1004013. eCollection 2023 Jun.
5
Unlocking the DOOR-how to design, apply, analyse, and interpret desirability of outcome ranking endpoints in infectious diseases clinical trials.解锁 DOOR-如何在传染病临床试验中设计、应用、分析和解释结局排序偏好的方法。
Clin Microbiol Infect. 2023 Aug;29(8):1024-1030. doi: 10.1016/j.cmi.2023.05.003. Epub 2023 May 12.
6
Coronavirus Disease 2019 Vaccination Is Associated With Reduced Outpatient Antibiotic Prescribing in Older Adults With Confirmed Severe Acute Respiratory Syndrome Coronavirus 2: A Population-Wide Cohort Study.新型冠状病毒疾病 2019 疫苗接种与确诊严重急性呼吸综合征冠状病毒 2 的老年患者门诊抗生素处方减少相关：一项基于人群的队列研究。
Clin Infect Dis. 2023 Aug 14;77(3):362-370. doi: 10.1093/cid/ciad190.
7
Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis.定植携带患者中多重耐药革兰氏阴性菌和万古霉素耐药肠球菌感染的发生率：系统评价和荟萃回归分析。
Lancet Infect Dis. 2023 Jun;23(6):719-731. doi: 10.1016/S1473-3099(22)00811-8. Epub 2023 Jan 30.
8
Innovation for infection prevention and control-revisiting Pasteur's vision.创新感染预防与控制——重温巴斯德的愿景。
Lancet. 2022 Dec 17;400(10369):2250-2260. doi: 10.1016/S0140-6736(22)02459-X.
9
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.莫努匹韦与安慰剂在英国早期 SARS-CoV-2 感染未接种疫苗和已接种疫苗患者中的比较（AGILE CST-2）：一项随机、安慰剂对照、双盲、2 期临床试验。
Lancet Infect Dis. 2023 Feb;23(2):183-195. doi: 10.1016/S1473-3099(22)00644-2. Epub 2022 Oct 19.
10
The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe.金黄色葡萄球菌网络自适应平台试验方案：旧敌新工具。
Clin Infect Dis. 2022 Nov 30;75(11):2027-2034. doi: 10.1093/cid/ciac476.
Zotero 插件